Abstracts tagged "hpv"

Abstract Number: 0984 • ACR Convergence 2021
Human Papillomavirus Infection Increases Risk of Primary Sjogren’s Syndrome: A Population-based Cohort Study over a 15-year Follow-up
Kevin Sheng-Kai Ma, Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philidelphia, PA
Background/Purpose: Viral infection has been considered as an exogeneous risk factor for primary Sjogren’s syndrome (pSS). We determined whether human papillomavirus (HPV) infection was associated…
Abstract Number: 1720 • ACR Convergence 2021
Cervical Dysplasia and HPV Infection in Women with Vasculitis
Taylor Koenig¹, Ambra Burrell², Hilary Kleppel³, Ashlee Weaver⁴, Veronica Mruk⁵, Lynn Fussner¹, Salem Almaani⁶ and Alexa Meara¹, ¹Ohio State University Wexner Medical Center, Columbus, OH, ²Division of Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Wright State University, Blacklick, OH, ⁴Ohio State University College of Medicine, Columbus, OH, ⁵Ohio State University / Nationwide Children's Hospital, Columbus, OH, ⁶Ohio State University Medical Center, Columbus, OH
Background/Purpose: The most common cause of cervical cancer is persistent human papillomavirus (HPV) infection in the cervical epithelium, causing precancerous cervical dysplasia and ultimately cervical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].